Cabozantinib in advanced renal cell carcinoma: a METEOR impact on clinical practice

Affiliations

Editorial

Paolo Grassi et al. Transl Androl Urol. 2016 Dec.

. 2016 Dec;5(6):974-976.

doi: 10.21037/tau.2016.11.06.

¹ Department of Medical Oncology, Genitourinary Cancer Unit, Fondazione IRCCS Istituto Nazionale Tumori, Milano, Italy.

No abstract available

Conflict of interest statement

The authors have no conflicts of interest to declare.

Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial.
Choueiri TK, Escudier B, Powles T, Tannir NM, Mainwaring PN, Rini BI, Hammers HJ, Donskov F, Roth BJ, Peltola K, Lee JL, Heng DYC, Schmidinger M, Agarwal N, Sternberg CN, McDermott DF, Aftab DT, Hessel C, Scheffold C, Schwab G, Hutson TE, Pal S, Motzer RJ; METEOR investigators. Choueiri TK, et al. Lancet Oncol. 2016 Jul;17(7):917-927. doi: 10.1016/S1470-2045(16)30107-3. Epub 2016 Jun 5. Lancet Oncol. 2016. PMID: 27279544 Clinical Trial.

1. Choueiri TK, Escudier B, Powles T, et al. Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial. Lancet Oncol 2016;17:917-27. 10.1016/S1470-2045(16)30107-3 - DOI - PubMed
1. Motzer RJ, Escudier B, McDermott DF, et al. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med 2015;373:1803-13. 10.1056/NEJMoa1510665 - DOI - PMC - PubMed
1. Motzer RJ, Escudier B, Oudard S, et al. Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer 2010;116:4256-65. 10.1002/cncr.25219 - DOI - PubMed
1. NCT01835158. Cabozantinib-s-malate or Sunitinib Malate in Treating Patients With Previously Untreated Locally Advanced or Metastatic Kidney Cancer. Available online: https://clinicaltrials.gov/ct2/show/NCT01835158
1. Cella D, Grünwald V, Nathan P, et al. Quality of life in patients with advanced renal cell carcinoma given nivolumab versus everolimus in CheckMate 025: a randomised, open-label, phase 3 trial. Lancet Oncol 2016;17:994-1003. 10.1016/S1470-2045(16)30125-5 - DOI - PMC - PubMed